Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study

PLoS Medicine

Volumn 12, Issue 6, 2015, Pages

  Grandjean, Louis ^a,b,c   Gilman, Robert H ^b,d   Martin, Laura ^b   Soto, Esther ^b   Castro, Beatriz ^b   Lopez, Sonia ^b   Coronel, Jorge ^b   Castillo, Edith ^e   Alarcon, Valentina ^f   Lopez, Virginia ^g   San Miguel, Angela ^g   Quispe, Neyda ^h   Asencios, Luis ^h   Dye, Christopher ⁱ   Moore, David A J ^b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e Laboratorio de Mycobacteriologia   (Peru)

^f MINISTERIO DE SALUD   (Peru)

^g Ministerio de Salud   (Peru)

^h INSTITUTO NACIONAL DE SALUD   (Peru)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMOPROPHYLAXIS; CHILD; COHORT ANALYSIS; DISEASE TRANSMISSION; DRUG SENSITIVITY; EVALUATION AND FOLLOW UP; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; PROSPECTIVE STUDY; SCHOOL CHILD; SOCIOECONOMICS; STRUCTURED QUESTIONNAIRE; YOUNG ADULT; FAMILY SIZE; INCIDENCE; PERU; TRANSMISSION; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; FAMILY CHARACTERISTICS; FEMALE; HUMANS; INCIDENCE; MALE; PERU; PROSPECTIVE STUDIES; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84937786194     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001843     Document Type: Article

References (29)

1. Cohen T, Sommers B, Murray M, The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis. 2003;3:13–21. 12505028
2. Andersson DI, Persistence of antibiotic resistant bacteria. Curr Opin Microbiol. 2003;6:452–456. 14572536
3. Cohen T, Murray M, Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med. 2004;10:1117–1121. 15378056
4. Dye C, Espinal MA, Will tuberculosis become resistant to all antibiotics? Proc Biol Sci. 2001;268:45–52. 12123297
5. Dye C, Williams BG, Espinal MA, Raviglione MC, Erasing the world’s slow stain: strategies to beat multidrug-resistant tuberculosis. Science. 2002;295:2042–2046. 11896268
6. Mitchison DA, Tubercle bacilli resistant to isoniazid; virulence and response to treatment with isoniazid in guinea-pigs. BMJ. 1954;1:128–130. 13106496
7. Middlebrook G, Cohn ML, Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science. 1953;118:297–299. 13089681
8. García-García ML, Ponce de León A, Jiménez-Corona ME, Jiménez-Corona A, Palacios-Martínez M, Balandrano-Campos S, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med. 2000;160:630–636. 10724048
9. Van Soolingen D, Borgdorff MW, de Haas PE, Sebek MM, Veen J, Dessens M, et al. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis. 1999;180:726–736. doi: 10.1086/314930 10438361
10. Burgos M, DeRiemer K, Small PM, Hopewell PC, Daley CL, Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis. 2003;188:1878–1884. doi: 10.1086/379895 14673768
11. Gagneux S, Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect. 2009;15 (Suppl 1):66–68. doi: 10.1111/j.1469-0691.2008.02685.x 19220360
12. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ, The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006;312:1944–1946. 16809538
13. Davies AP, Billington OJ, Bannister BA, Weir WR, McHugh TD, Gillespie SH, Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment. J Infect. 2000;41:184–187. doi: 10.1053/jinf.2000.0711 11023769
14. Teixeira L, Perkins MD, Johnson JL, Keller R, Palaci M, do Valle Dettoni V, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001;5:321–328. 11334250
15. Attamna A, Chemtob D, Attamna S, Fraser A, Rorman E, Paul M, et al. Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort. Thorax. 2009;64:271. doi: 10.1136/thx.2008.100974 19252032
16. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011;377:147–152. doi: 10.1016/S0140-6736(10)61972-1 21145581
17. Morrison J, Pai M, Hopewell PC, Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:359–368. doi: 10.1016/S1473-3099(08)70071-9 18450516
18. Grandjean L, Crossa A, Gilman RH, Herrera C, Bonilla C, Jave O, et al. Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis. 2011;15:1164–1169, i. doi: 10.5588/ijtld.11.0030 21943839
19. Peruvian Ministry of Health. Norma tecnica de salud para el control de la tuberculosis. Lima: Peruvian Ministry of Health; 2006. NTS No. 039-MINSA/DGSP-V.0.1. Available: http://www.minsa.gob.pe/portada/esntbc_tbnormas.asp#. Accessed 21 May 2015.
20. Caviedes L, Lee TS, Gilman RH, Sheen P, Spellman E, Lee EH, et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru. J Clin Microbiol. 2000;38:1203–1208. 10699023
21. Moore DA, Mendoza D, Gilman RH, Evans CA, Hollm Delgado MG, Guerra J, et al. Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings. J Clin Microbiol. 2004;42:4432–4437. 15472289
22. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35:907–914. 9157152
23. Grandjean L, Gilman RH, Martin L, Soto E, Castro B, Lopez S, et al. Transmission of multidrug-resistant and drug susceptible tuberculosis within households: a prospective cohort study. Dryad Digital Repository. Available: http://dx.doi.org/10.5061/dryad.br760. Accessed 29 May 2015.
24. Rogers WH, Regression standard errors in clustered samples. Stata Tech Bull. 1993;13:19–23.
25. Ordway DJ, Sonnenberg MG, Donahue SA, Belisle JT, Orme IM, Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice. Infect Immun. 1995;63:741–743. 7822053
26. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014. Available: http://www.who.int/tb/publications/global_report/en/. Accessed 5 December 2014.
27. Drobniewski F, Balabanova Y, Nikolayevsky V, Ruddy M, Kuznetzov S, Zakharova S, et al. Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA. 2005;293:2726–2731. doi: 10.1001/jama.293.22.2726 15941801
28. Cohen T, Murray M, Abubakar I, Zhang Z, Sloutsky A, Arteaga F, et al. Multiple introductions of multidrug-resistant tuberculosis into households, Lima, Peru. Emerg Infect Dis. 2011;17:969–975. doi: 10.3201/eid/1706.101471 21749756
29. Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VØ, Andersen AB, Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis. 2002;185:401–404. doi: 10.1086/338342 11807725